DK1455781T3 - Anvendelse af anastrozol til behandling af post-menopausale kvinder, der har tidlig brystkræft - Google Patents

Anvendelse af anastrozol til behandling af post-menopausale kvinder, der har tidlig brystkræft

Info

Publication number
DK1455781T3
DK1455781T3 DK02783305T DK02783305T DK1455781T3 DK 1455781 T3 DK1455781 T3 DK 1455781T3 DK 02783305 T DK02783305 T DK 02783305T DK 02783305 T DK02783305 T DK 02783305T DK 1455781 T3 DK1455781 T3 DK 1455781T3
Authority
DK
Denmark
Prior art keywords
breast cancer
anastrozole
post
early breast
treatment
Prior art date
Application number
DK02783305T
Other languages
Danish (da)
English (en)
Inventor
Paul Plourde
Anthony Rogers
Brent Vose
Michael Dukes
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1455781(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1455781T3 publication Critical patent/DK1455781T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Treatment Of Metals (AREA)
DK02783305T 2001-12-10 2002-12-06 Anvendelse af anastrozol til behandling af post-menopausale kvinder, der har tidlig brystkræft DK1455781T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129457.8A GB0129457D0 (en) 2001-12-10 2001-12-10 Method of treatment
PCT/GB2002/005554 WO2003053438A1 (en) 2001-12-10 2002-12-06 Use of anastrozole for the treatment of post-menopausal women having early breast cancer

Publications (1)

Publication Number Publication Date
DK1455781T3 true DK1455781T3 (da) 2008-11-24

Family

ID=9927290

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02783305T DK1455781T3 (da) 2001-12-10 2002-12-06 Anvendelse af anastrozol til behandling af post-menopausale kvinder, der har tidlig brystkræft

Country Status (29)

Country Link
US (1) US20050165081A1 (xx)
EP (2) EP1455781B1 (xx)
JP (2) JP5335173B2 (xx)
KR (1) KR100858946B1 (xx)
CN (1) CN100408036C (xx)
AT (1) ATE406160T1 (xx)
AU (1) AU2002347371B2 (xx)
BR (1) BR0214798A (xx)
CA (1) CA2468965C (xx)
CO (1) CO5590926A2 (xx)
CY (1) CY1108462T1 (xx)
DE (1) DE60228616D1 (xx)
DK (1) DK1455781T3 (xx)
ES (1) ES2303811T3 (xx)
GB (1) GB0129457D0 (xx)
HK (1) HK1069335A1 (xx)
HU (1) HUP0402023A3 (xx)
IL (1) IL162150A0 (xx)
IS (1) IS7300A (xx)
MX (1) MXPA04005394A (xx)
NO (1) NO20042912L (xx)
NZ (1) NZ533106A (xx)
PL (1) PL369411A1 (xx)
PT (1) PT1455781E (xx)
RU (1) RU2320339C2 (xx)
SI (1) SI1455781T1 (xx)
UA (1) UA79443C2 (xx)
WO (1) WO2003053438A1 (xx)
ZA (1) ZA200404260B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
WO2005089511A2 (en) * 2004-03-19 2005-09-29 Transform Pharmaceuticals, Inc. Novel pharmaceutical forms, and methods of making and using the same
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
CN100337625C (zh) * 2004-08-30 2007-09-19 鲁南制药集团股份有限公司 阿那曲唑的分散片剂型
CN1304054C (zh) * 2004-12-29 2007-03-14 山东蓝金生物工程有限公司 一种缓慢释放的抗癌药物组合物
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
WO2011130381A1 (en) * 2010-04-13 2011-10-20 Estrocept Diagnostics, Inc. Diagnostic assays for breast cancer treatment and progression
US10201549B2 (en) 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
CN103450099B (zh) * 2013-09-06 2015-03-25 杭州华东医药集团新药研究院有限公司 阿那曲唑及其一水合物的新晶型、制备和用途
RU2548722C1 (ru) * 2013-12-06 2015-04-20 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство пролонгированного действия на основе противоопухолевого препарата, ингибитора синтеза эстрогенов - анастрозола
DE102014005513B4 (de) * 2014-04-15 2018-03-15 Sanoxsys Gmbh Mittel zur Prävention und Therapie von Tumorerkrankungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714013D0 (en) * 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
AR034142A1 (es) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
EP1455781A1 (en) 2004-09-15
KR20040066886A (ko) 2004-07-27
CY1108462T1 (el) 2014-04-09
HUP0402023A2 (hu) 2005-01-28
DE60228616D1 (de) 2008-10-09
SI1455781T1 (sl) 2008-12-31
CA2468965A1 (en) 2003-07-03
RU2004121162A (ru) 2005-05-20
PL369411A1 (en) 2005-04-18
RU2320339C2 (ru) 2008-03-27
AU2002347371B2 (en) 2007-05-10
MXPA04005394A (es) 2005-04-19
BR0214798A (pt) 2004-10-19
CN100408036C (zh) 2008-08-06
UA79443C2 (en) 2007-06-25
HUP0402023A3 (en) 2008-08-28
EP1997492A1 (en) 2008-12-03
CA2468965C (en) 2011-08-30
ES2303811T1 (es) 2008-09-01
JP2011016828A (ja) 2011-01-27
GB0129457D0 (en) 2002-01-30
IS7300A (is) 2004-06-04
EP1455781B1 (en) 2008-08-27
JP2005516021A (ja) 2005-06-02
NO20042912L (no) 2004-08-25
ES2303811T3 (es) 2009-02-01
ATE406160T1 (de) 2008-09-15
IL162150A0 (en) 2005-11-20
NZ533106A (en) 2008-02-29
KR100858946B1 (ko) 2008-09-17
CN1630519A (zh) 2005-06-22
HK1069335A1 (en) 2005-05-20
AU2002347371A1 (en) 2003-07-09
PT1455781E (pt) 2008-11-03
JP5335173B2 (ja) 2013-11-06
WO2003053438A1 (en) 2003-07-03
ZA200404260B (en) 2005-10-26
US20050165081A1 (en) 2005-07-28
CO5590926A2 (es) 2005-12-30

Similar Documents

Publication Publication Date Title
HK1069335A1 (en) Use of anastrozole for the treatment of post-menopausal women having early breast cancer
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
MY127290A (en) New use of flibanserin
DE50310516D1 (de) Fredericamycin-derivate
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
HUP0301460A2 (hu) Antiprogresztinek használata hormonfüggő betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállításához
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
AU2003217397A8 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
PT883401E (pt) Antagonista do receptor at1 para estimulacao da apoptose
DE50211672D1 (de) Urokinase-inhibitoren
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
DE69912477D1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
RS16804A (xx) Upotreba 4-piridilmetilftalazina u lečenju raka
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
PT1401446E (pt) Derivados de tetrahidroquinolina para a inibicao de doencas associadas com a privacao de estrogenio ou com uma resposta fisiologica aberrante ao estrogenio endogeno
GB0216027D0 (en) New therapeutic use
EP1385497A4 (en) METHOD FOR PREVENTING OR TREATING BREAST CANCER, PROSTATE AND / OR COLUMN OF UTERUS USING N, N-DIMETHYLGLYCIN
UA67528A (en) Method for surgical treatment of thyroid cancer
TW527918U (en) Medical chest strap dedicated for breast cancer patient
GB0110908D0 (en) Proreins, genes and their use for diagnosis and treatment of breast cancer